RUNX2 and metabolic dysfunction-associated steatotic liver disease: These outcomes, altogether, demonstrate that RANKL is involved in Runx2-induced hepatic infiltration of macrophages in NAFLD, which reveals an underlying therapeutic target for NAFLD.